Preparedness in action: Securing Europe’s future against health emergencies

Given the many challenges Europe is currently facing, defense and security have naturally risen to the top of the EU political agenda. In a tense geopolitical context, with a war on its doorstep and the lingering effects of the COVID-19 pandemic, the EU and its member states must prepare for increasingly complex, cross-border threats. In the aftermath of the pandemic, Europe has taken action to better anticipate future health threats, as evidenced by the establishment of the European Health Emergency Preparedness and Response Authority (HERA) and creation of rescEU, a “strategic reserve of European disaster response capabilities and stockpiles”. While these efforts at the European level are unprecedented, Europe has not yet reached the level of civilian and military preparedness and readiness needed to face future challenges effectively. In October 2024, in a report commissioned by President von der Leyen, former Finnish President Sauli Niinistö stressed the urgency for Europe to adopt a “more comprehensive and integrated approach” for relevant stakeholders to “be fully ready and capable to respond effectively and seamlessly, as part of a wider whole-of-government and whole-of-society approach”. Now is the time to connect these policy ambitions with operational realities.    

Currently, the stockpiling of "medical countermeasures" involves numerous stakeholders navigating fragmented public services, regulatory discrepancies across EU member states, and the absence of a Europe-wide policy framework. The management of supply chains is a challenge for manufacturers of countermeasures such as medicines, vaccines, diagnostic tests and personal protective equipment. In the context of the ongoing review of HERA, now is the time to assess current strategies, responsibilities, policy gaps and funding mechanisms. As the EU and member states have started negotiating the next Multiannual Financial Framework and potential increases in defense spending, Europe has a unique opportunity to strengthen its capacity alongside this to better protect its citizens from health and bioterrorism threats, as a core component of the broader security and defense agenda.

Against this backdrop, several aspects warrant further debate and consideration:

• What supply chain vulnerabilities must Europe address to efficiently manage and swiftly deploy countermeasures, strengthen its security capabilities and ensure preparedness for future health threats?
• How to better connect HERA’s field of action (e.g. joint procurements and stockpiling of “medical countermeasures”) with operations at the national level?
• How to ensure sustainable stockpiling solutions through stable funding instruments?
• How can companies and public-private partnerships contribute to improving the efficiency of preparedness mechanisms and building optimal stockpiles of medical countermeasures?
• What policy measures are required to stimulate the production of innovative medical countermeasures, ensuring that research and innovation efforts focus on the practical application of their outcomes in line with EU policy priorities?
• How to divide, coordinate and integrate military and civil protection strategies to increase preparedness?
• How can regional, national, European, and international governance levels better align to ensure the security of European citizens?

On June 4th, Science|Business, in partnership with Emergent BioSolutions and EUCOPE, will convene a selected group of key stakeholders that face those operational issues, to address them collectively and produce a set of practical recommendations to inform the policy-making process currently underway.